The Times – Our flu drug is not to be sniffed at, says Poolbeg Pharma chief Jeremy Skillington June 21, 2021 – Posted in: Blog, Open Orphan (ORPH) – Tags: , , , , , , ,

Jeremy Skillington wants to develop a “conveyor belt of therapies” after focusing on influenza

The course of Jeremy Skillington’s year took a fateful turn in March when he took a call from Cathal Friel, chairman of Open Orphan, a clinical trials company listed on the Alternative Investment Market (AIM). At the time Skillington was tidying up the loose ends of the landmark €380 million sale of Irish biotech company Inflazome to Roche, a Swiss pharmaceutical multinational, and plotting three months of leisure.

Donegal deal-maker Friel dangled the dizzying prospect of heading an Irish biotech company that would list on the stock market within three to six months.

Link here for the full article